Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2553)	8/6/2009 2:18:56 PM
From: Jibacoa	Respond to of 3722

MSHL, the Australian company also has been showing some periodic spikes, but still needs to keep above the $1 level.<g> bigcharts.marketwatch.com It announced yesterday that it was paying $1.5M to NVGN as front payment to license NV-128 It also had licensed from NVGN phenoxodiol, which is on PIII for ovarian cancer and also been tested for prostatic Ca. MSHL has negligible LTD. It has been trimming its losses in the last 3Qs in spite of lower revenues.The stock remains on its longer term DT but has been forming a base and with some good news and if can keep above $1 it seems it could make it to the $2 level.<g> bigcharts.marketwatch.com Bernard